What is VIP? A Research Guide.

VIP is a 28-amino-acid neuropeptide involved in communication across several physiological systems. Its name reflects its early characterization, while later work describes roles beyond the intestine.[1]

VIP is released by neurons and immune cells, and several cell types express receptors that respond to it. This distribution helps explain why reviews describe neurotransmission, vascular effects, secretion and immune signalling in the same article. These are multiple context-dependent biological functions, not one uniform response. A naturally occurring signal can have different effects depending on the receptor, tissue and experimental conditions; administering an external material is a separate pharmacological question.[1][2]

Research reviews discuss receptor signalling and interactions with immune and nervous-system processes. These papers help explain endogenous biology: what VIP does within biological systems under the conditions studied.[1]

The immune-function review was published in 2013, despite its earlier PubMed record history. It synthesizes VIP production, receptor signalling and research in inflammatory or autoimmune contexts; it does not enroll a trial population. The 1999 pharmaceutical review discusses receptor chemistry, drug design and delivery challenges. These sources map a research field rather than demonstrating a specific treatment outcome for a pen formulation.[1][2]

The pharmaceutical review describes the challenges of translating a broadly active peptide into a defined intervention. Receptor activity, experimental anti-inflammatory observations and endogenous physiological roles are not interchangeable with demonstrated clinical outcomes.[1][2]

These sources do not establish that an afiya VIP pen improves recovery, treats inflammation or is suitable for human administration. The catalog category is a browsing aid, not a clinical indication.

The breadth of VIP’s endogenous actions is also a reason not to assume external administration has a simple or predictable result. Receptor selectivity, tissue exposure and formulation are unresolved product-specific questions here. A review’s discussion of potential pharmaceutical uses is not confirmation of clinical effectiveness or a safe exposure pattern.[1][2]